Page last updated: 2024-11-03

prazosin and Autosomal Dominant Juvenile Parkinson Disease

prazosin has been researched along with Autosomal Dominant Juvenile Parkinson Disease in 4 studies

Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.
prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.

Research Excerpts

ExcerptRelevanceReference
"We found slower disease progression, decreased PD-related complications, and a reduced frequency of PD diagnoses in individuals taking TZ and related drugs."1.51Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases. ( Cai, R; Chen, Z; Consiglio, A; Fernandez-Carasa, I; Gao, L; Han, Y; Ji, X; Li, Y; Liu, L; Narayanan, NS; Polgreen, PM; Raya, A; Schultz, JL; Simmering, JE; Su, W; Welsh, MJ; Yuan, Y; Zhang, Y; Zhao, C, 2019)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (50.00)29.6817
2010's2 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cai, R1
Zhang, Y1
Simmering, JE1
Schultz, JL1
Li, Y1
Fernandez-Carasa, I1
Consiglio, A1
Raya, A1
Polgreen, PM1
Narayanan, NS1
Yuan, Y1
Chen, Z1
Su, W1
Han, Y1
Zhao, C1
Gao, L1
Ji, X1
Welsh, MJ1
Liu, L1
Özkan, M1
Johnson, NW1
Sehirli, US1
Woodhall, GL1
Stanford, IM1
Archer, T1
Fredriksson, A1
Seppi, K1
Puschban, Z1
Stefanova, N1
Scherfler, C1
Mueller, J1
Poewe, W1
Wenning, GK1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
a Randomized, Double Blind, Placebo Controlled Clinical Trial Exploring the Target Engagement and Tolerability of Terazosin Hydrochloride in Patients With Dementia With Lewy Bodies[NCT04760860]Phase 1/Phase 240 participants (Anticipated)Interventional2024-10-31Not yet recruiting
The Effect of alpha1- Adrenergic Receptor Antagonist Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease: A Follow up Study[NCT05109364]Phase 215 participants (Anticipated)Interventional2022-09-23Recruiting
Assessing Target Engagement of Terazosin in Healthy Adults[NCT04551040]Phase 118 participants (Anticipated)Interventional2021-03-26Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Other Studies

4 other studies available for prazosin and Autosomal Dominant Juvenile Parkinson Disease

ArticleYear
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
    The Journal of clinical investigation, 2019, 10-01, Volume: 129, Issue:10

    Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros

2019
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
    The Journal of clinical investigation, 2019, 10-01, Volume: 129, Issue:10

    Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros

2019
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
    The Journal of clinical investigation, 2019, 10-01, Volume: 129, Issue:10

    Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros

2019
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
    The Journal of clinical investigation, 2019, 10-01, Volume: 129, Issue:10

    Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros

2019
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
    The Journal of clinical investigation, 2019, 10-01, Volume: 129, Issue:10

    Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros

2019
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
    The Journal of clinical investigation, 2019, 10-01, Volume: 129, Issue:10

    Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros

2019
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
    The Journal of clinical investigation, 2019, 10-01, Volume: 129, Issue:10

    Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros

2019
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
    The Journal of clinical investigation, 2019, 10-01, Volume: 129, Issue:10

    Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros

2019
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
    The Journal of clinical investigation, 2019, 10-01, Volume: 129, Issue:10

    Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros

2019
Dopamine acting at D1-like, D2-like and α1-adrenergic receptors differentially modulates theta and gamma oscillatory activity in primary motor cortex.
    PloS one, 2017, Volume: 12, Issue:7

    Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adrenergic alpha-1 Receptor Agonists; Ad

2017
An antihypokinesic action of alpha2-adrenoceptors upon MPTP-induced behaviour deficits in mice.
    Journal of neural transmission (Vienna, Austria : 1996), 2003, Volume: 110, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Clonidine; Dopamine; Dopamine Agonists; Drug I

2003
Overstimulation of the alpha1B-adrenergic receptor causes a "seizure plus" syndrome.
    Nature medicine, 2001, Volume: 7, Issue:2

    Topics: Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Brain; Cerebral Cortex; Disease Models,

2001
chemdatabank.com